Skip to content

KEEL KEEL Issuance of warrants to purchase common stock

Issuance of warrants to purchase common stock at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%
NovaGold Resources logo
NovaGold ResourcesNG
$9.9M
KEE
Keel Infrastructure Corp. Common StockKEEL
$11.48M
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%
Applied Digital logo
Applied DigitalAPLD
$121.2M+232%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$0

Other financials

Income statement

See full
Revenue$37.0M-22.4%
Gross profit-$26.3M-9,631%
Operating income-$98.4M-182%
Net income-$145.4M-162%
EPS (diluted)-$0.24-118%

Balance sheet

See full
Cash & equivalents$357.3M+827%
Total debt$591.0M
Total equity$419.1M-36.6%
Total assets$1.1B

Cash flow

See full
Operating cash flow-$64.7M-243%
CapEx$10.3M-76.2%
Free cash flow-$75.0M-20.6%

Valuation

See full
Market cap$3.99B

Profitability

See full
Gross margin-7.9%-2.8pp
Operating margin-37.8%+2.0pp
Net margin-52%+24.6pp
FCF margin-259.9%+201pp

Returns & leverage

See full
Return on equity-6.1%-2.5pp
Debt / equity1.4×
Current ratio9.6×

Where this comes from

Reported directly by KEEL in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: KEEL’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about KEEL's issuance of warrants to purchase common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KEEL's issuance of warrants to purchase common stock?
KEEL (KEEL) reported issuance of warrants to purchase common stock of $11.48M in Q1 2025.
What does issuance of warrants to purchase common stock mean?
Represents the accounting value assigned to warrants issued to investors or third parties, which grant the right to purchase common stock at a specified price. This metric reflects the cost of equity-linked financing and the potential for future dilution. It provides transparency into the company's use of non-cash compensation or financing incentives.